Unknown

Dataset Information

0

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.


ABSTRACT: Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

SUBMITTER: Young K 

PROVIDER: S-EPMC4622287 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.

Young Kate K   Smyth Elizabeth E   Chau Ian I  

Therapeutic advances in gastroenterology 20151101 6


Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides  ...[more]

Similar Datasets

| S-EPMC5057500 | biostudies-literature
| S-EPMC7205241 | biostudies-literature
| S-EPMC4966750 | biostudies-literature
| S-EPMC8576210 | biostudies-literature
| S-EPMC3437538 | biostudies-literature
| S-EPMC8436782 | biostudies-literature
| S-EPMC9425884 | biostudies-literature
| S-EPMC9664295 | biostudies-literature
| S-EPMC2768436 | biostudies-other
| S-EPMC8229851 | biostudies-literature